{"id":"https://openalex.org/W2560194709","doi":"https://doi.org/10.1182/blood.v128.22.3541.3541","title":"Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)","display_name":"Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2560194709","doi":"https://doi.org/10.1182/blood.v128.22.3541.3541","mag":"2560194709"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.3541.3541","doi":"https://doi.org/10.1182/blood.v128.22.3541.3541","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.3541.3541","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080670916","display_name":"Shaloo Gupta","orcid":"https://orcid.org/0000-0002-2535-2892","observed_orcids":["https://orcid.org/0000-0002-2535-2892"]},"institutions":[{"id":"https://openalex.org/I4210152879","display_name":"Kantar Health (United States)","ror":"https://ror.org/04zbgcp34","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152879"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Shaloo Gupta","raw_affiliation_strings":["Health Outcomes Practice, Kantar Health, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Outcomes Practice, Kantar Health, Princeton, NJ","institution_ids":["https://openalex.org/I4210152879"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057941456","display_name":"G. Binder","orcid":"https://orcid.org/0000-0003-4912-7013","observed_orcids":["https://orcid.org/0000-0003-4912-7013"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Gary Binder","raw_affiliation_strings":["Celgene Corporation, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055740968","display_name":"Mikkael Aaron Sekeres","orcid":"https://orcid.org/0000-0003-2009-6524","observed_orcids":["https://orcid.org/0000-0003-2009-6524"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikkael A. Sekeres","raw_affiliation_strings":["Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086233229","display_name":"Aziz Nazha","orcid":"https://orcid.org/0000-0002-6695-7994","observed_orcids":["https://orcid.org/0000-0002-6695-7994"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aziz Nazha","raw_affiliation_strings":["Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016810759","display_name":"Hetty E. Carraway","orcid":"https://orcid.org/0000-0001-5241-3614","observed_orcids":["https://orcid.org/0000-0001-5241-3614"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hetty E. Carraway","raw_affiliation_strings":["Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082190063","display_name":"Stephanie Hawthorne","orcid":"https://orcid.org/0000-0002-9504-1600","observed_orcids":["https://orcid.org/0000-0002-9504-1600"]},"institutions":[{"id":"https://openalex.org/I4210152879","display_name":"Kantar Health (United States)","ror":"https://ror.org/04zbgcp34","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152879"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Stephanie Hawthorne","raw_affiliation_strings":["Health Outcomes Practice, Kantar Health, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Outcomes Practice, Kantar Health, Princeton, NJ","institution_ids":["https://openalex.org/I4210152879"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041948879","display_name":"Kristen King-Concialdi","orcid":"https://orcid.org/0000-0002-9612-3595","observed_orcids":["https://orcid.org/0000-0002-9612-3595"]},"institutions":[{"id":"https://openalex.org/I4210152879","display_name":"Kantar Health (United States)","ror":"https://ror.org/04zbgcp34","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152879"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristen King-Concialdi","raw_affiliation_strings":["Health Outcomes Practice, Kantar Health, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Outcomes Practice, Kantar Health, Princeton, NJ","institution_ids":["https://openalex.org/I4210152879"]}]},{"author_position":"last","author":{"id":null,"display_name":"Michael McGuire","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael McGuire","raw_affiliation_strings":["Celgene Corporation, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ","institution_ids":["https://openalex.org/I4387155837"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5057941456","https://openalex.org/A5080670916","https://openalex.org/A5082190063"],"corresponding_institution_ids":["https://openalex.org/I4210152879","https://openalex.org/I4387155837"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.14473212,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"128","issue":"22","first_page":"3541","last_page":"3541"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9789999723434448,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9789999723434448,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.003800000064074993,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13374","display_name":"Hematological disorders and diagnostics","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9620000123977661},{"id":"https://openalex.org/keywords/transfusion-dependence","display_name":"transfusion dependence","score":0.9769999980926514},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.8550000190734863},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.8759999871253967},{"id":"https://openalex.org/keywords/erythropoiesis-stimulating-agents","display_name":"erythropoiesis-stimulating agents","score":0.9739999771118164},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.9120000004768372},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.984000027179718},{"id":"https://openalex.org/keywords/decitabine","display_name":"decitabine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/transfusion-independence","display_name":"transfusion independence","score":0.9150000214576721},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.5320000052452087},{"id":"https://openalex.org/keywords/physician-survey","display_name":"physician survey","score":0.492000013589859},{"id":"https://openalex.org/keywords/del-5q","display_name":"del(5q)","score":0.6880000233650208},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.4580000042915344}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8606128692626953},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7145766615867615},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.6472187638282776},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.625299334526062},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.6168296337127686},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.6131711602210999},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5174739956855774},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.4990239143371582},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.46644139289855957},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4189569056034088},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.40434205532073975},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.35045742988586426},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.20530816912651062},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.10046109557151794},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.3541.3541","doi":"https://doi.org/10.1182/blood.v128.22.3541.3541","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.3541.3541","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2610927789","https://openalex.org/W2980244424","https://openalex.org/W2923836498","https://openalex.org/W2964113509","https://openalex.org/W2739779296","https://openalex.org/W4401340562","https://openalex.org/W4292451978","https://openalex.org/W2537994188","https://openalex.org/W2982745118","https://openalex.org/W2079770519"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Approximately":[2],"50%":[3],"of":[4,22,27,86,97,105,166,190,255,269,327,335,342,350,358,366,378,404,414,468,478,500,504,535,553,571,596,607,627],"patients":[5,50,98,118,270,299,310,317,329,344,360,379,482,536,563],"with":[6,13,24,51,58,99,292],"MDS":[7,125,155,168,231,264,481,519,573],"are":[8,80],"anemic":[9],"at":[10,122,183],"initial":[11,429],"diagnosis,":[12],"many":[14],"becoming":[15,181,221],"transfusion":[16,29],"dependent":[17],"(TD),":[18],"necessitating":[19],"the":[20,102,187,206,323,373,401,415,469,494,550,569],"introduction":[21],"therapy":[23,331,346,362,382,393,450,501,539,554],"a":[25,59,333,348,364,521],"goal":[26],"achieving":[28],"independence":[30],"(TI).":[31],"In":[32,372],"addition":[33],"to":[34,37,45,112,177,212,220,436,454,513,557],"transfusions,":[35,297],"treatments":[36],"improve":[38],"hemoglobin":[39,446],"levels":[40],"have":[41],"historically":[42],"been":[43],"limited":[44],"erythropoiesis-stimulating":[46],"agents":[47],"(ESAs),":[48],"whereas":[49],"more":[52],"advanced":[53],"disease":[54,89,214,237,523],"may":[55],"require":[56],"treatment":[57,76,93,108,239,245,390,506,526,566],"hypomethylating":[60],"agent":[61],"(HMA)":[62],"(azacitidine":[63],"[AZA]":[64],"or":[65,68,88,123,215,227,487,598,609,629],"decitabine":[66],"[DAC])":[67],"lenalidomide":[69],"(LEN).":[70],"As":[71],"there":[72],"is":[73,509,520,555],"no":[74,433],"predetermined":[75],"course,":[77,507],"these":[78],"therapies":[79],"continued":[81,529],"until":[82],"unacceptable":[83],"toxicity,":[84],"lack/loss":[85],"response,":[87],"progression.":[90],"We":[91],"examined":[92],"patterns,":[94],"clinical":[95,232],"outcome(s)":[96],"MDS,":[100],"and":[101,140,149,180,242,249,280,315,356,412,418,444,466,472,561],"physician's":[103],"report":[104],"reason":[106,387,497],"for":[107,244,389,425,498,540,545],"discontinuation":[109,246,391,426,499],"(previously":[110],"shown":[111],"vary":[113],"from":[114,136],"patients'":[115],"perspectives)":[116],"in":[117,229,409,463,510,515,524,568],"who":[119,210,380,537],"became":[120],"TD":[121,154,182,193,263,479],"after":[124],"diagnosis":[126,165,284],"(Gerds":[127],"et":[128],"al.":[129],"Blood":[130],"2014;124:abstract":[131],"2642).":[132],"Methods:Data":[133],"were":[134,228,234,247,278,301,312,319],"derived":[135],"disease-specific":[137],"physician":[138,492],"surveys":[139],"patient":[141],"charts,":[142],"which":[143,407,508,525],"provided":[144,258],"information":[145,259],"on":[146,152,260,549,592,603,623],"demographic,":[147],"treatment,":[148],"outcome":[150],"data":[151],"lower-risk":[153,262,480],"patients.":[156,265,574],"Patient":[157],"inclusion":[158],"criteria":[159],"were:":[160],"age":[161,268],"\u2265":[162,199],"18":[163],"years,":[164],"Low/Intermediate-risk":[167],"(International":[169],"Prognostic":[170],"Scoring":[171],"System":[172],"defined)":[173],"2-6":[174,289],"years":[175,273,287],"prior":[176,219],"study":[178],"entry,":[179],"least":[184],"once":[185],"during":[186,205],"minimum":[188],"follow-up":[189,207,324],"24":[191],"months.":[192],"was":[194,271,285,398,457,502],"defined":[195],"as":[196,518],"having":[197],"received":[198],"2":[200],"transfusions":[201],"within":[202],"8":[203],"weeks":[204],"period.":[208],"Patients":[209],"progressed":[211],"higher-risk":[213],"acute":[216],"myeloid":[217],"leukemia":[218],"TD,":[222],"had":[223,307,383],"an":[224,230,593,604,624],"additional":[225],"malignancy,":[226],"trial":[233],"excluded.":[235],"Demographics,":[236],"history,":[238,240],"TI,":[241],"reasons":[243,424,542],"collected":[248],"reported":[250,395,423,458],"descriptively.":[251],"Results:":[252],"A":[253],"total":[254],"239":[256],"physicians":[257,397,560],"1,221":[261],"The":[266,385,532],"median":[267,281,334,349,365],"65":[272],"(range":[274,288],"27-95":[275],"years),":[276],"56.3%":[277],"male,":[279],"time":[282],"since":[283],"3.2":[286],"years).":[290],"Along":[291],"packed":[293],"red":[294],"blood":[295],"cell":[296],"354":[298],"(29%)":[300],"prescribed":[302,313,320],"LEN":[303,359],"[of":[304],"whom":[305],"12.7%":[306],"del(5q)],":[308],"348":[309],"(28.5%)":[311],"ESAs,":[314,485],"32":[316],"(2.6%)":[318],"HMAs.":[321],"During":[322],"period,":[325],"31.3%":[326],"ESA":[328],"discontinued":[330,345,361,381,489],"(at":[332,347,363],"12":[336],"months;":[337,352,368],"range":[338,353,369],"3-47":[339],"months),":[340,355],"32%":[341],"HMA":[343,419,473],"10":[351],"3-52":[354],"26%":[357],"13":[367],"2-30":[370],"months).":[371],"LEN-treated":[374],"group,":[375],"only":[376],"9.8%":[377],"del(5q).":[384],"main":[386],"cited":[388],"across":[392],"groups":[394],"by":[396],"\"patients":[399,432],"completing":[400],"scheduled":[402,505],"course":[403],"treatment\"":[405],"(28.2%),":[406],"occurred":[408],"32.6%,":[410],"20.2%,":[411],"22.6%":[413],"LEN,":[416,470,484],"ESA,":[417,471],"groups,":[420,451,474],"respectively.":[421,475],"Other":[422],"included":[427],"\"insufficient":[428],"response\"":[430],"(20.0%),":[431],"longer":[434],"responding":[435],"therapy\"":[437,456],"(19.0%),":[438],"\"disease":[439],"progression\"":[440],"(18.0%),":[441],"\"death\"":[442],"(13.3%),":[443],"\"worsening":[445],"levels\"":[447],"(12.8%).":[448],"Across":[449],"\"patient":[452],"preference":[453],"stop":[455,538],"less":[459],"frequently":[460],"(9.7%),":[461],"occurring":[462],"7.6%,":[464],"8.3%,":[465],"12.9%":[467],"Conclusions:Over":[476],"30%":[477],"receiving":[483],"AZA,":[486],"DAC":[488],"therapy.":[490],"Per":[491],"reports,":[493],"most":[495],"frequent":[496],"completion":[503],"stark":[511],"contrast":[512],"recommendations":[514],"consensus":[516],"guidelines,":[517],"chronic":[522],"should":[527],"be":[528],"ad":[530],"infinitum.":[531],"significant":[533],"number":[534],"alternative":[541],"suggests":[543],"opportunities":[544],"further":[546],"investigation.":[547],"Education":[548],"expected":[551],"duration":[552],"essential":[556],"help":[558],"support":[559],"inform":[562],"about":[564],"optimal":[565],"decisions":[567],"care":[570],"all":[572],"Disclosures":[575],"Gupta:":[576],"Kantar":[577],"Health:":[578,633,641],"Employment;":[579,634,642],"Celgene":[580,612,635,643],"Corporation:":[581,586,613,636,644,649],"Consultancy,":[582,637,645],"Research":[583,614,638,646],"Funding.":[584,639,647],"Binder:Celgene":[585],"Employment,":[587,650],"Equity":[588,651],"Ownership.":[589,652],"Carraway:Incyte:":[590],"Membership":[591,602,622],"entity's":[594,605,625],"Board":[595,606,626],"Directors":[597,608,628],"advisory":[599,610,630],"committees;":[600,611],"Novartis:":[601],"Funding,":[615],"Speakers":[616,619],"Bureau;":[617,620],"Baxalta:":[618],"Amgen:":[621],"committees.":[631],"Hawthorne:Kantar":[632],"King-Concialdi:Kantar":[640],"McGuire:Celgene":[648]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-12-16T00:00:00"}